Nsclc
Role of KRAS in NSCLC: present and future
Authors: Addeo A, Bini R
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite therapeutic advances over the last several decades, the overall 5-year survival remains only 16%. (Siegel R, 2013). Molecular studies have indicated that Adenocarcinomas have distinct genomic alterations allowing classification into clinically relevan.. Read More»
- Genet. Mol. Res. 17(1):
- gmr16039873
- DOI:
- 10.4238/gmr16039873
Clinical significance of fascin-1 and laminin-5 in non-small cell lung cancer
Authors: L. Yang, Y. Teng, T.-P. Han, F.-G. Li, W.-T. Yue and Z.-T. Wang
Lung cancer is the leading cause of cancer death in men and the second leading cause of cancer death in women worldwide. Fascin-1 and laminin-5 were associated with the invasiveness and prognoses of several cancers. The expression and the serum levels of fascin-1 and laminin-5 in patients with non-small cell lung cancer (NSCLC.. Read More»
- Genet. Mol. Res. 16(2):
- gmr16029617
- DOI:
- 10.4238/gmr16029617
Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer
Authors: D.J. Chu, D.E. Yao, Y.F. Zhuang, Y. Hong, X.C. Zhu, Z.R. Fang, J. Yu and Z.Y. Yu
Although new chemotherapeutic drugs have been applied constantly, their efficacy for non-small cell lung cancer (NSCLC) is still not satisfactory. In recent years, epidemiological investigations have shown that lung cancer may be induced by chronic Chlamydia pneumoniae (Cpn) infection, since stable high titers of Cpn antibodie.. Read More»
- Genet. Mol. Res. 13(2):
- 2014.April.14.8
- DOI:
- 10.4238/2014.April.14.8
Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer
Authors: Z.Y. Jin, X.T. Zhao, L.N. Zhang, Y. Wang, W.T. Yue and S.F. Xu
This study aimed to investigate the effects of single-nucleotide polymorphisms (SNPs) XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met, XPG His104Asp, and XPG His46His in genes involved in the DNA-repair pathway on the outcomes of platinum-based chemothera.. Read More»
- Genet. Mol. Res. 13(3):
- 2014.March.31.13
- DOI:
- 10.4238/2014.March.31.13
Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer
Authors: X.F. Jia, J. Li, H.B. Zhao, J. Liu and J.J. Liu
The aim of this study was to explore epidermal growth factor receptor (EGFR) gene amplification and its relationship with cancer invasion and metastasis in non-small cell lung cancer (NSCLC). EGFR amplification in 45 patients with NSCLC and 15 subjects with normal lung tissues was detected by fluorescence in situ hybridization. The relationship between EG.. Read More»
- Genet. Mol. Res. 14(3):
- http://dx.doi.org/2015.September.21.13
- DOI:
- http://dx.doi.org/10.4238/2015.September.21.13
Glutathione S-transferase pi polymorphism contributes to the treatment outcomes of advanced non-small cell lung cancer patients in a Chinese population
Authors: J.B. Chen, F. Wang, J.J. Wu and M. Cai
We analyzed the association between polymorphisms in three glutathione S-transferase genes (GSTP1, GSTM1, and GSTT1) and the treatment outcome for advanced non-small cell lung cancer (NSCLC). We recruited 284 NSCLC patients at advanced stage from Department of Radiotherapy in Peace Hospital Attached to Changzhi Medical College between May 2009 and May 201.. Read More»
- Genet. Mol. Res. 15(3):
- gmr.15037498
- DOI:
- 10.4238/gmr.15037498
Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients
Authors: K.F. Ma, X.Y. Chu and Y. Liu
The aim of this retrospective study was to evaluate the prognostic influence of lymphatic vessel invasion (LVI) in stage I non-small cell lung cancer (NSCLC) patients. From January 2004 to December 2007, LVI was detected in 57 patients with T1N0M0 NSCLC; therefore, 114 patients with the same pathology, T stage, and surgery method, but without LVI, were se.. Read More»
- Genet. Mol. Res. 14(1):
- 2015.March.13.10
- DOI:
- 10.4238/2015.March.13.10
Roles of ERĂ?± and ERĂ?² in estrogen-induced DDP chemoresistance in non-small cell lung cancer
Authors: N. Yu, L. Dou, Y. Li, L. Deng, X. Wei and Y. Guo
The role of estrogen in inducing chemoresistance is not yet fully understood. The objective of this study was to observe the relationship between estrogen levels and cellular response to chemotherapeutic drugs in non-small cell lung cancer (NSCLC) and to reveal the potential mechanisms involved. Cell viability was analyzed after pre-treating NSCLC cells w.. Read More»
- Genet. Mol. Res. 15(3):
- gmr.15038995
- DOI:
- 10.4238/gmr.15038995
Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics
Authors: H.F. Liu, J.S. Liu, J.H. Deng and R.R. Wu
Non-small cell lung cancer (NSCLC) is the most common cancer globally. The XRCC1 protein interacts with ligase and poly(ADP-ribose) polymerase to repair cisplatin-induced DNA damage. The authors of previous studies have reported XRCC1 Arg399Gln, Arg280His, and Arg194Trp polymorphisms and advanced NSCLC prognosis, but the resul.. Read More»
- Genet. Mol. Res. 15(4):
- gmr15049084
- DOI:
- 10.4238/gmr15049084
Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population
Authors: H.L. Xiao, Z.T. Yang, F. Han and H.X. Wei
The aim of this study was to evaluate the association of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymorphisms with the chemotherapy response and overall survival of advanced NSCLC. Two hundred and sixty-two patients with histologically confirmed advanced NSCLC (inoperable TNM stages IIIA, IIIB, and IV) wer.. Read More»
- Genet. Mol. Res. 15(2):
- gmr.15027320
- DOI:
- 10.4238/gmr.15027320